sq 28603 has been researched along with pindolol in 1 studies
| Studies (sq 28603) | Trials (sq 28603) | Recent Studies (post-2010) (sq 28603) | Studies (pindolol) | Trials (pindolol) | Recent Studies (post-2010) (pindolol) |
|---|---|---|---|---|---|
| 35 | 0 | 0 | 3,718 | 662 | 92 |
| Protein | Taxonomy | sq 28603 (IC50) | pindolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.0005 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.0009 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 0.088 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.048 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.048 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
1 review(s) available for sq 28603 and pindolol
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |